Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases

Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases

Background/Objectives: Hereditary angioedema (HAE) is a rare genetic condition marked by recurring episodes of intense swelling that affect the skin, gastrointestinal system, and airways. Lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, is approved for long-term prophylaxis (LTP)...

Full description

Saved in:
Bibliographic Details
Main Authors: Inmaculada Sánchez-Machín, Ruperto González-Pérez, Elena Mederos-Luis, Sara García-Gil, Paloma Poza-Guedes
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Allergies
Subjects:
hereditary angioedema
HAE
healthcare resource
C1 inhibitor
bradykinin
lanadelumab
Online Access:https://www.mdpi.com/2313-5786/5/1/3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2313-5786/5/1/3

Similar Items